About
Marcus Bosenberg, MD, PhD, is the Anthony N. Brady Professor of Dermatology, Pathology and Immunobiology at Yale School of Medicine. He serves as Director of the Yale SPORE in Skin Cancer, Director of the Yale Center for Immuno-Oncology, Co-Leader of the Cancer Immunology Program at Yale Cancer Center, and Director of the Center for Precision Cancer Modeling. As a practicing dermatopathologist at Yale Medicine, he specializes in diagnosing skin cancers and inflammatory disorders.
Education & Training:
- BA, Cornell University (1986)
- PhD, Cornell University Medical College (1993)
- MD, Cornell University Medical College (1994)
- Residency: Brigham & Women's Hospital
- Fellowships: Harvard Medical School Dermatopathology, Dana-Farber Cancer Institute
Research Focus: Dr. Bosenberg's laboratory investigates melanoma biology, anti-cancer immune responses, metastasis mechanisms, and therapeutic development. His team pioneered mouse models for melanoma progression and therapy testing, with strong emphases on tumor microenvironment interactions, epigenetic regulation of immunity, and precision cancer modeling. Key research areas include BRAF/MEK signaling pathways, DNA methylation in immunotherapy resistance, and nanoparticle-based drug delivery systems.
Publication Trends: His recent articles (2023-2025) demonstrate a strong focus on melanoma immunotherapy resistance mechanisms, tumor microenvironment modulation, and diagnostic innovations. Epigenetic regulation (e.g., DNA methylation, Setdb1) emerges as a recurrent theme, alongside novel approaches to enhance T-cell responses and overcome immune evasion. Nanotechnology applications for targeted drug delivery and advanced molecular diagnostics feature prominently in his translational work.
Awards:
- Yale School of Medicine Basic Science Research Prize (2022)
Mentoring & Leadership: Dr. Bosenberg mentors undergraduate, graduate, and medical students along with postdoctoral fellows. He directs multiple research centers and leads the Yale SPORE in Skin Cancer, focusing on translational melanoma research. His laboratory develops patient-derived tumor models for renal cell carcinoma and melanoma studies.